Abstract: Objective To evaluate the clinical efficacy and the side effects of icotinib in treatment of brain metastases from nonsmall cell lung cancer（NSCLC）. Methods Thirty-one cases of NSCLC with brain metastases who received icotinib were reviewed. All of them were treated with icotinib（125mg， 3 times a day）until disease progression or unacceptable toxicities, and 25 patients of them received brain radiotherapy. Results In terms of intracranial lesions，the response rate（RR） and disease control rate（DCR）were 25.8％ and 83.9％. As for systemic disease，RR and DCR were 38.7％ and 87.1％. Patients who received brain radiation had better RR than those without brain radiation（P＞0.05）. RR and DCR were not related to age，gender，pathological types，PS score，brain metastases，icotinib administration, brain radiotherapy and epidermal growth factor receptor（EFGR） mutation. The median progressionfree survival（PFS）was 6.5 months（95%CI:4.787-8.213 months），while it in EGFR mutation patients was 10.1 months. PFS was related to EGFR mutation status，and not to other clinical pathological features. The common side effects of icotinib were rash，dry skin and diarrhea，mainly in grade 1-2. Conclusion Icotinib may be effective on brain metastases in NSCLC patients，and the toxicities are tolerable，which worth further study.